Clinical Report: COMO and CAPRI Trials Evaluate Duravyu in DME
Overview
The COMO and CAPRI trials are phase 3 studies assessing Duravyu, a tyrosine kinase inhibitor, in patients with diabetic macular edema (DME). These trials aim to determine if Duravyu can achieve similar visual outcomes to aflibercept while reducing treatment burden.
Background
Diabetic macular edema is a significant cause of vision impairment in diabetic patients, and current treatments primarily involve anti-VEGF therapies. However, a substantial proportion of patients do not respond adequately to these therapies, highlighting the need for alternative treatment options. The COMO and CAPRI trials are designed to evaluate the efficacy and safety of Duravyu, which targets multiple pathways involved in DME.
Data Highlights
No numerical data available in the source material.
Key Findings
- The trials aim to enroll approximately 240 patients each, comparing Duravyu to aflibercept.
- Primary endpoint is noninferior change from baseline in best-corrected visual acuity (BCVA).
- Secondary endpoints include safety, reduction in treatment burden, and anatomic results measured by OCT.
- Duravyu is administered every 6 months, compared to aflibercept every 8 weeks.
- Duravyu targets VEGF, PDGF, and IL-6 pathways, potentially addressing treatment-resistant cases.
Clinical Implications
The findings from the COMO and CAPRI trials could provide insights into a new treatment paradigm for DME, particularly for patients who do not respond to existing therapies. If successful, Duravyu may offer a longer-lasting treatment option, reducing the frequency of patient visits and injections.
Conclusion
The COMO and CAPRI trials represent a significant step in exploring alternative therapies for DME, with the potential to improve patient outcomes and reduce treatment burden. Continued evaluation of Duravyu will be essential in determining its role in clinical practice.
References
- EyePoint Pharmaceuticals, Ophthalmology Management, 2026 -- EyePoint Initiates Phase 3 Trials of Duravyu for DME
- EyePoint Pharmaceuticals, Retinal Physician, 2026 -- EyePoint Begins Phase 3 Trials of Duravyu for DME
- Jennifer Ford, Retinal Physician, 2024 -- Supplemental Injection Data From DAVIO 2 Trial of EYP-1901 Presented at ASRS
- Ophthalmology Management, 2025 -- 4DMT Presents Positive 60 Week Results from 4D150 SPECTRA Clinical Trial in DME
- PubMed, Diabetic Retinopathy Preferred Practice Pattern® -- Clinical Guidelines
- EyePoint, EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema, 2026
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed
- EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema - EyePoint, Inc.
- Efficacy of fluocinolone acetonide implant in diabetic macular edema patients previously treated with dexamethasone implant: A systematic review and meta-analysis - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
